October 23, 2016 3:23 AM ET


Company Overview of MicroBiome Therapeutics, LLC

Company Overview

MicroBiome Therapeutics, LLC, a biotechnology company, develops medical food and pharmaceutical products. The company focuses on developing evidence-based microbiome modulators, which are designed to alter bacteria populations and their environment in the gastrointestinal tract in specific ways to treat and prevent serious health conditions. Its product includes NM504, which contains a combination of prebiotic and other naturally occurring ingredients formulated to help diabetic individuals achieve healthy blood glucose levels and manage their body weight. MicroBiome Therapeutics, LLC was formerly known as NuMe Health LLC. The company was founded in 2009 and is based in Broomfield, Colorado.

11001 W 120th Avenue

Suite 400

Broomfield, CO 80021

United States

Founded in 2009

Key Executives for MicroBiome Therapeutics, LLC

Co-Founder and Chairman
Age: 67
Co-Founder and Director
Age: 59
Chief Scientific Officer and Vice President of Research
Compensation as of Fiscal Year 2016.

MicroBiome Therapeutics, LLC Key Developments

MicroBiome Therapeutics Receives Positive Response from FDA for Use of Expedited Regulatory Pathway for Diabetes Drug NM505

MicroBiome Therapeutics LLC reported that the U.S. Food & Drug Administration (FDA) has responded positively to the company's pre-IND request to use the 505(b)(2) abbreviated regulatory pathway for development of lead product NM505. This pathway allows the use of existing safety and efficacy data on the drug's key active ingredient along with relevant data in the public domain to reduce the size, scope, timeline and cost of the clinical program required for FDA submission and review.

Steve Orndorff to Resign as CEO of MicroBiome Therapeutics LLC at the End of May 2015

MicroBiome Therapeutics LLC announced that CEO Steve Orndorff will be resigning at the end of May 2015 to head up a new biopharmaceutical venture close to his home.

MicroBiome Therapeutics Receives Notice Of Allowance For U.S. Patent Covering Glyceollin As a Treatment For Diabetes And Obesity

MicroBiome TherapeuticsTM LLC (MBT) reported that the U.S. Patent and Trademark Office has issued a notice of allowance for the company's patent application covering the use of glyceollin to treat diabetes and obesity. MBT is investigating glyceollins for the treatment of metabolic disorders, including diabetes and obesity, as well as their potential role in modulating the gastrointestinal microbiome. Glyceollin I, II and III are small molecule natural products made by soy plants under certain environmental conditions to help combat infectious organisms and other stressors. In animal studies, glyceollins have demonstrated activity in a number of human disease models, including breast and ovarian cancer, hyper-cholesterolemia and metabolic disorders. MBT also announced that it is participating in the One-on-One Partnering sessions of the 17th Annual BIO CEO and Investor Conference in New York City.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact MicroBiome Therapeutics, LLC, please visit www.mbiome.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.